Table 2.

Rotavirus Immunoglobulin A Seroconversion and Geometric Mean Titers by Concomitant Versus Staggered Oral Poliovirus Vaccine Administration^a

Study Arm and Timing of RV1 and OPV Administration	Infants, No.	Rotavirus IgA Seroconversion (95% CI), %	P Valueb	Rotavirus IgA Titer, GMT (95% CI)	P Valuec
Total (n = 409)
Concomitant	174	47 (39–54)	.001	60 (45–80)	.001
Staggered	235	63 (57–70)		116 (91–149)
RV1 + mOPV1 (n = 149)
Concomitant	70	49 (37–60)	.10	63 (40–102)	.04
Staggered	79	62 (51–73)		126 (79–195)
RV1 + bOPV (n = 154)
Concomitant	72	47 (36–59)	.04	54 (35–83)	.01
Staggered	82	65 (53–75)		123 (83–182)
RV1 + tOPV (n = 106)
Concomitant	32	41 (24–59)	.04	68 (33–135)	.23
Staggered	74	64 (52–74)		102 (63–162)

Abbreviations: bOPV, bivalent oral poliovirus vaccine (OPV); CI, confidence interval; GMT, geometric mean titer; IgA, immunoglobulin A; mOPV1, monovalent OPV type 1; RV1, monovalent rotavirus vaccine; tOPV, trivalent OPV.

^aSeroconversion was defined as a ≥4 fold rise in IgA titer from baseline to post dose 2. Concomitant administration was defined as any RV1 dose given together with any OPV dose. Staggered administration was defined as RV1 and OPV doses given ≥1 day apart.

^bBased on χ² tests.

^cBased on Mann–Whitney tests.